Innovation in Development of Dermatologic Drugs Approved by the US Food and Drug Administration Between 2012 and 2022 DOI
Samir Kamat, Benjamin Ungar, Aneesh Agarwal

et al.

JAMA Dermatology, Journal Year: 2023, Volume and Issue: 160(2), P. 226 - 226

Published: Dec. 20, 2023

This cross-sectional study characterizes the frequency and degree of innovation new dermatologic drugs approved by US Food Drug Administration (FDA) from 2012 to 2022.

Language: Английский

Use of Efficiency Frontiers to Align Prices and Clinical Benefits of Biologic Therapies for Plaque Psoriasis DOI
Alexander C. Egilman, Aaron S. Kesselheim, Jerry Avorn

et al.

JAMA Dermatology, Journal Year: 2024, Volume and Issue: 160(4), P. 409 - 409

Published: Feb. 21, 2024

The US lacks a systematic approach for aligning drug prices with clinical benefit, and traditional cost-effectiveness analysis (CEA) faces political obstacles. efficiency frontier (EF) method offers policymakers an alternative approach.

Language: Английский

Citations

9
Availability and Coverage of New Drugs in 6 High-Income Countries With Health Technology Assessment Bodies DOI
Olivier J. Wouters, Huseyin Naci, Irene Papanicolas

et al.

JAMA Internal Medicine, Journal Year: 2024, Volume and Issue: 184(3), P. 328 - 328

Published: Jan. 29, 2024

This cohort study analyzes review times and approval outcomes of health technology assessments conducted in 6 high-income countries for novel therapeutic agents approved by the US Food Drug Administration.

Language: Английский

Citations

5
Therapeutic Benefit of Top-Selling Oncology Drugs in Medicare DOI Creative Commons
Stephanie Wang, Alexander C. Egilman, Georg Hahn

et al.

JAMA Network Open, Journal Year: 2025, Volume and Issue: 8(4), P. e253323 - e253323

Published: April 4, 2025

This cohort study examines whether international health technology assessment reviews may identify oncology drugs that are suitable for aggressive price negotiation.

Language: Английский

Citations

0
Estimated Savings From Using Added Therapeutic Benefit and Therapeutic Reference Pricing in United States Medicare Drug Price Negotiations DOI Creative Commons
Michael J. DiStefano, Joseph Levy, Ilina C. Odouard

et al.

Value in Health, Journal Year: 2023, Volume and Issue: 26(11), P. 1618 - 1624

Published: Sept. 7, 2023

This study describes and estimates savings from a specific approach Medicare could use to determine an initial offer price for drug negotiations.

Language: Английский

Citations

4
For what it's worth: the complex area of medicine value assessment DOI Creative Commons
Sreeram V Ramagopalan,

C. Treharne,

Jonathan Pearson‐Stuttard

et al.

Journal of Comparative Effectiveness Research, Journal Year: 2023, Volume and Issue: 12(9)

Published: July 29, 2023

Language: Английский

Citations

3
Clinical Benefit and Revenues of Drugs Affected by Rare Pediatric Disease Priority Review Vouchers, 2017-2023 DOI

Ian T. T. Liu,

Aaron S. Kesselheim

The Journal of Pediatrics, Journal Year: 2024, Volume and Issue: 275, P. 114211 - 114211

Published: July 24, 2024

Language: Английский

Citations

0
Gauging the Value of Top-Selling Drugs in Medicare—Reply DOI
Alexander C. Egilman, Benjamin N. Rome, Aaron S. Kesselheim

et al.

JAMA, Journal Year: 2023, Volume and Issue: 330(7), P. 665 - 665

Published: Aug. 15, 2023

Our website uses cookies to enhance your experience. By continuing use our site, or clicking "Continue," you are agreeing Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals Network Open Cardiology Dermatology Health Forum Internal Medicine Neurology Oncology Ophthalmology Otolaryngology–Head & Neck Surgery Pediatrics Psychiatry Archives of (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions LibrariansReprints Permissions Terms Use Privacy Accessibility Statement 2023 American Association. All Rights Reserved Search Archive Input Term Sign In Individual inCreate an Account Access through institution Purchase Options: Buy this article Rent Subscribe the journal

Language: Английский

Citations

1
Protecting Medicare’s Discretion to Say No to Unproven Therapies DOI Open Access

C. Joseph Ross Daval,

Liam Bendicksen, Aaron S. Kesselheim

et al.

JAMA, Journal Year: 2023, Volume and Issue: 330(12), P. 1133 - 1133

Published: Sept. 8, 2023

In this Viewpoint, Kesselheim and coauthors discuss 2 bills in Congress that would curtail Medicare’s ability to decline, limit, or conditionally cover medical products lack robust evidence argue officials should distinguish between better worse therapies when determining reimbursement.

Language: Английский

Citations

1
Rethinking Innovation in Drugs: A Pathway to Health for All DOI Creative Commons
Mariana Mazzucato

The Journal of Law Medicine & Ethics, Journal Year: 2023, Volume and Issue: 51(S2), P. 16 - 20

Published: Jan. 1, 2023

Abstract This article discusses the misalignment of drug innovation model in US with broader societal goals. The paper calls for a reconfiguration this to prioritize common good and ensure equitable access health innovations. stresses importance adopting mission-oriented approach shape market, including reforming intellectual property rights.

Language: Английский

Citations

1
How Do the Institute for Clinical and Economic Review’s Assessments of Comparative Effectiveness Compare With the German Federal Joint Committee’s Assessments of Added Benefit? A Qualitative Study DOI
Michael J. DiStefano,

Steven D. Pearson,

David M. Rind

et al.

Value in Health, Journal Year: 2024, Volume and Issue: 27(8), P. 1066 - 1072

Published: April 26, 2024

Language: Английский

Citations

0